Latest On Antibe Therapeutics Inc (ATBPF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-15 20:37 EST | News | Antibe Therapeutics GAAP EPS of -$0.08 | N/A |  |
| 2022-11-15 13:59 EST | News | Antibe Therapeutics GAAP EPS of -$0.12 misses by $0.03 | N/A | |
| 2022-08-15 09:41 EST | News | Antibe Therapeutics Inc. GAAP EPS of -$0.10 misses by $0.02 | N/A | |
| 2022-06-30 23:38 EST | News | Antibe Therapeutics Inc. GAAP EPS of -$0.50 misses by $0.06 | N/A | |
| 2022-02-14 22:25 EST | News | Antibe Therapeutics GAAP EPS of -$0.09 | N/A | |
| 2021-11-16 14:34 EST | News | Antibe Therapeutics reports FQ2 results | N/A | |
| 2021-08-17 07:26 EST | News | Antibe Therapeutics reports FQ1 results | N/A | |
| 2021-07-22 17:07 EST | News | Antibe Therapeutics teams up with Dalriada Drug Discovery to accelerate pipeline expansion | N/A | |
| 2021-07-22 17:06 EST | News | Antibe Therapeutics, Inc. reports FY results | N/A | |
| 2021-05-01 02:25 EST | News | Antibe Therapeutics (ATBPF) Investor Presentation - Slideshow | N/A | |
| 2021-02-14 06:03 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-12 13:07 EST | News | Antibe Therapeutics reports Q3 results | N/A | |
| 2020-12-04 06:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-01 15:19 EST | Stock Split | A stock split has occured on Dec 1, 2020 with a split factor of 1:10. | Neutral | |
| 2020-11-27 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 19:24 EST | News | Antibe Therapeutics reports Q2 results | N/A | |
| 2020-10-08 21:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-26 03:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-25 00:08 EST | News | Antibe Therapeutics reports Q1 results | N/A | |
| 2020-08-14 12:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 03:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-25 19:36 EST | News | Antibe Therapeutics reports FY results | N/A | |
| 2020-07-23 21:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 16:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-09 17:51 EST | News | Antibe Therapeutics: A Closer Look At Their Top-Line Results, Part 2 | N/A | |
| 2020-06-09 17:50 EST | News | Antibe secures $25M capital raise | N/A | |
| 2020-06-07 19:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:27 EST | Financials | Company financials have been released. | Neutral | |
About Antibe Therapeutics Inc (ATBPF):
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
General
- Name Antibe Therapeutics Inc
- Symbol ATBPF
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 47
- Last Split Factor1:10
- Last Split Date2020-12-01
- Fiscal Year EndMarch
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.antibethera.com
Valuation
- Forward PE 73.53
- Price/Sales (Trailing 12 Mt.) 17.29
- Price/Book (Most Recent Quarter) 12.55
- Enterprise Value Revenue 16.72
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -292%
- Return on Assets -76%
- Return on Equity -217%
- Earnings Per Share -$0.04
- Revenue Per Share $0
- Gross Profit 3.89 million
- Quarterly Earnings Growth 9.4%
Highlights
- Market Capitalization 187.88 million
- Book Value Per Share $0.02
Share Statistics
- Shares Outstanding 45.51 million
- Shares Float 36.69 million
- % Held by Insiders 263%
- % Held by Institutions 0.15%
Technicals
- Beta -0.02
- 52 Week High $5.88
- 52 Week Low $0.23
- 50 Day Moving Average 3.97
- 200 Day Moving Average 2.75
Dividends
- Dividend Date 2020-12-01
- ExDividend Date N/A
- Dividend Yield 0%
Antibe Therapeutics Inc (ATBPF) Dividend Calendar:
ATBPF's last dividend payment was made to shareholders on December 1, 2020.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Antibe Therapeutics Inc (ATBPF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | -$0.13 | ||
| 2020-09-30 | 2020-11-12 | $2.87 million | -$0.20 | -$0.10 | -100% |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.15 | -$0.10 | -54.9% |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.12 | ||
| 2019-12-31 | 2020-03-31 | $2.61 million | -$0.16 | -$0.01 | -1494% |
| 2019-09-30 | 2019-12-31 | $2.27 million | -$0.12 | -$0.01 | -1060% |
| 2019-06-30 | 2019-09-30 | $2.76 million | -$0.14 | -$0.01 | -1314% |
| 2019-03-31 | 2019-06-30 | $2.43 million | -$0.10 | ||
| 2018-12-31 | 2019-03-31 | $2.5 million | -$0.14 | -$0.01 | -1341% |
| 2018-09-30 | 2018-12-31 | $2.07 million | -$0.11 | ||
| 2018-06-30 | 2018-09-30 | $1.93 million | -$0.09 | ||
| 2018-03-31 | 2018-06-30 | $20855.03 | -$0.10 | ||
| 2017-12-31 | 2018-03-31 | $1.78 million | -$0.11 | ||
| 2017-09-30 | 2017-12-31 | $1.43 million | -$0.08 | ||
| 2017-06-30 | 2017-09-30 | $1.75 million | -$0.09 | ||
| 2017-03-31 | 2017-06-30 | $1.71 million | -$0.11 | ||
| 2016-12-31 | 2017-03-31 | $1.46 million | -$0.12 | ||
| 2016-09-30 | 2016-12-31 | $1.67 million | -$0.14 | ||
| 2016-06-30 | 2016-09-30 | $2.04 million | -$0.09 | ||
| 2016-03-31 | 2016-06-30 | $1.79 million | -$0.10 | ||
| 2015-12-31 | 2016-03-31 | $1.52 million | -$0.15 | ||
| 2015-09-30 | 2015-12-31 | $N/A | -$0.07 | ||
| 2015-06-30 | 2015-09-30 | $N/A | -$0.11 | ||
| 2015-03-31 | 2015-06-30 | $N/A | -$0.06 | ||
| 2014-12-31 | 2015-03-31 | $N/A | -$0.14 | ||
| 2014-09-30 | 2014-12-31 | $N/A | -$0.20 | -$0.04 | -411.5% |
| 2014-06-30 | 2014-09-30 | $N/A | -$0.31 | -$0.05 | -516.6% |
| 2014-03-31 | 2014-06-30 | $N/A | -$0.41 | $0.00 | |
| 2013-12-31 | 2014-03-31 | $N/A | -$0.27 | $0.00 | |
| 2013-09-30 | 2013-12-31 | $N/A | -$0.32 | $0.00 | |
| 2013-06-30 | 2013-09-30 | $N/A | -$0.20 | $0.00 | |
| 2013-03-31 | 2013-06-30 | $N/A | -$0.14 | $0.00 | |
| 2012-12-31 | 2013-03-31 | $N/A | -$0.14 | $0.00 | |
| 2012-09-30 | 2012-12-31 | $N/A | -$0.18 | $0.00 | |
| 2012-06-30 | 2012-09-30 | $N/A | -$0.12 | $0.00 | |
| 2012-03-31 | 2012-06-30 | -$0.09 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.30 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.09 | $0.00 |
Antibe Therapeutics Inc (ATBPF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Antibe Therapeutics Inc (ATBPF) Chart:
Antibe Therapeutics Inc (ATBPF) News:
Below you will find a list of latest news for Antibe Therapeutics Inc (ATBPF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Antibe Therapeutics Inc (ATBPF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Antibe Therapeutics Inc (ATBPF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2013-08-09 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1583682/000158368213000001/0001583682-13-000001-index.htm |
| 2019-08-29 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1583682/000158368219000002/0001583682-19-000002-index.htm |